DRTS - Alpha Tau rises 12% on FDA approval to begin trial of Alpha DaRT to treat skin cancer

Medical device maker Alpha Tau (NASDAQ:DRTS +11.9%) said on Wednesday the U.S. Food and Drug Administration conditionally approved its investigational device exemption application to begin multi-center study to treat recurrent cutaneous Squamous Cell Carcinoma (SCC) using its alpha-radiation cancer therapy Alpha DaRT. The study has been approved to enroll up to 86 U.S. patients at about 20 institutions, and will focus on patients with recurrent cutaneous SCC who have failed at least first line standard of care therapy and are not indicated for another curative standard of care therapy, the company said. Seeking Alpha contributor Avisol Capital Partners rated DRTS hold.

For further details see:

Alpha Tau rises 12% on FDA approval to begin trial of Alpha DaRT to treat skin cancer